BioCryst Pharmaceuticals, Inc. announced that new data regarding their oral once-daily drug ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be presented at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results